Supreme Pharmaceuticals Lists on Canadian Securities Exchange – Video News Alert on InvestmentPitch.com

Vancouver, British Columbia--(Newsfile Corp. - April 23, 2014) - Supreme Pharmaceuticals (CSE: SL) is one of the latest new listings on the Canadian Securities Exchange, and is trading under the symbol "SL". The company stated that its move from the TSX Venture Exchange will allow it to efficiently and seamlessly transition from a junior resource company to one whose main focus is now on the emerging medical marijuana field.

InvestmentPitch.com has produced a "video news alert" which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Supreme" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_wt8qc5qi/Supreme-Pharmaceuticals-CSE-SL-New-Listing

President and CEO, David Stadnyk stated: "Our goal is to secure several medical marijuana producing facilities, each with a MMPR license. There is no assurance that we will be able to secure such facilities. This is a critical year for MMPR licences and we plan on making several applications to Health Canada. While we have longstanding relationships with both the TSX Venture and the Canadian Securities Exchange, we believe this is the right move for the Company at this time. We now have two producing medical marijuana facilities under evaluation and expect to report positive news shortly."

The company has already signed a conditional agreement with an arms-length South Okanagan-based company giving Supreme the option to purchase its producing medical marijuana business.

The company, which until recently operated as Supreme Resources under the symbol SPR, would appear to be better suited that most companies to make this switch, as the current management team has a track record of finding and developing early stage pharmaceutical or biomedical device companies. The company also announced it has no plans to dispose of or shelve its mineral exploration properties, and will continue to work on them as the opportunities present themselves.

In September 2013, the company closed a private placement consisting of 79.9 million units $0.005, which contained a warrant to purchase a common share at $0.05 for a period of 12 months. The recent increase in the share price has facilitated the exercise of a significant number of these warrants, which allowed the company to cancel its recently announced private placement.

The shares are trading at $0.055, and with 145 million shares outstanding, the company is capitalized at $8 million.

For more information, please visit the company’s website, www.supremepharmaceuticals.com or contact David Stadnyk, President & CEO, at 647-340-6744 or email info@supremepharmaceuticals.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing short three minute videos based on significant news releases and research reports. Please visit InvestmentPitch.com and browse the extensive library of investment videos.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com